$CRBP
Corbus Pharmaceuticals Holdings, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022023282 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.554M $4.073M $4.235M
YoY Change 7.54% -22.81% -20.99%
% of Gross Profit
Research & Development $6.243M $4.108M $5.764M
YoY Change 8.31% -52.76% -64.22%
% of Gross Profit
Depreciation & Amortization $184.4K $190.8K $207.7K
YoY Change -11.21% -25.55% -25.83%
% of Gross Profit
Operating Expenses $10.80M $8.181M $9.998M
YoY Change 7.99% -41.45% -53.43%
Operating Profit -$8.181M
YoY Change -41.04%
Interest Expense -$357.8K -$678.0K -$372.0K
YoY Change -3.83% 103.13% -65.23%
% of Operating Profit
Other Income/Expense, Net $275.6K -$600.3K $109.7K
YoY Change 151.28% -105.13% -99.17%
Pretax Income -$10.88M -$8.782M -$10.26M
YoY Change 6.03% 303.54% 19.17%
Income Tax
% Of Pretax Income
Net Earnings -$10.88M -$8.782M -$10.26M
YoY Change 6.03% 303.54% 19.17%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$2.62 -$0.07 -$81.92K
COMMON SHARES
Basic Shares Outstanding 125.3M 125.3M 125.2M
Diluted Shares Outstanding 125.3M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.20M $66.23M $97.65M
YoY Change -39.38% -38.02% 14.34%
Cash & Equivalents $17.00M $12.44M $25.01M
Short-Term Investments $42.19M $53.79M $72.64M
Other Short-Term Assets $984.1K $1.119M $2.557M
YoY Change -61.52% -51.46% -37.62%
Inventory
Prepaid Expenses $1.094M
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $60.18M $67.35M $100.2M
YoY Change -39.94% -39.69% 8.83%
LONG-TERM ASSETS
Property, Plant & Equipment $1.614M $1.798M $2.393M
YoY Change -32.55% -32.22% -41.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $155.3K $133.1K $46.39K
YoY Change 234.91% -80.18%
Total Long-Term Assets $6.131M $6.483M $7.526M
YoY Change -18.53% -18.01% -26.37%
TOTAL ASSETS
Total Short-Term Assets $60.18M $67.35M $100.2M
Total Long-Term Assets $6.131M $6.483M $7.526M
Total Assets $66.31M $73.83M $107.7M
YoY Change -38.45% -38.26% 5.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.174M $1.374M $1.782M
YoY Change 21.98% -46.02% -75.85%
Accrued Expenses $5.999M $4.834M $10.09M
YoY Change -40.56% -63.84% -54.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.796M $9.884M $3.093M
YoY Change -9.62% 341.91%
Total Short-Term Liabilities $12.64M $17.47M $17.01M
YoY Change -25.68% 1.9% -46.68%
LONG-TERM LIABILITIES
Long-Term Debt $15.98M $9.386M $15.64M
YoY Change 2.23% -49.4% -13.27%
Other Long-Term Liabilities $22.21K $22.21K $22.21K
YoY Change 0.0% -99.64%
Total Long-Term Liabilities $16.01M $9.408M $15.66M
YoY Change 2.22% -49.28% -13.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.64M $17.47M $17.01M
Total Long-Term Liabilities $16.01M $9.408M $15.66M
Total Liabilities $33.32M $31.88M $38.62M
YoY Change -13.72% -23.99% -32.27%
SHAREHOLDERS EQUITY
Retained Earnings -$392.1M -$381.2M -$349.7M
YoY Change 12.11% 12.29% 15.01%
Common Stock $417.00 $12.53K $12.52K
YoY Change -96.67% 0.04% 26.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.99M $41.95M $69.11M
YoY Change
Total Liabilities & Shareholders Equity $66.31M $73.83M $107.7M
YoY Change -38.45% -38.26% 5.31%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$10.88M -$8.782M -$10.26M
YoY Change 6.03% 303.54% 19.17%
Depreciation, Depletion And Amortization $184.4K $190.8K $207.7K
YoY Change -11.21% -25.55% -25.83%
Cash From Operating Activities -$7.455M -$7.245M -$9.703M
YoY Change -23.16% -945.44% -46.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$54.17K
YoY Change -100.0% -190.28%
Acquisitions
YoY Change
Other Investing Activities $11.78M -$5.971M -$3.123M
YoY Change -477.17% -2201.82%
Cash From Investing Activities $11.78M -$5.971M -$3.177M
YoY Change -470.74% -2201.82% -5395.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 234.3K -110.7K 767.9K
YoY Change -69.49% 7.81% -96.47%
NET CHANGE
Cash From Operating Activities -7.455M -7.245M -9.703M
Cash From Investing Activities 11.78M -5.971M -3.177M
Cash From Financing Activities 234.3K -110.7K 767.9K
Net Change In Cash 4.559M -13.33M -12.11M
YoY Change -137.64% -1383.46% -440.23%
FREE CASH FLOW
Cash From Operating Activities -$7.455M -$7.245M -$9.703M
Capital Expenditures $0.00 $0.00 -$54.17K
Free Cash Flow -$7.455M -$7.245M -$9.648M
YoY Change -22.73% -945.44% -47.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-381201614
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001595097
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
dei Entity File Number
EntityFileNumber
001-37348
dei Entity Registrant Name
EntityRegistrantName
Corbus Pharmaceuticals Holdings, Inc.
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4348039
dei Entity Address Address Line1
EntityAddressAddressLine1
500 River Ridge Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Norwood
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02062
dei City Area Code
CityAreaCode
(617)
dei Local Phone Number
LocalPhoneNumber
963-0100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CRBP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
125280881
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12443645
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25006632
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
53785559
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
72640520
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
926161
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2365010
CY2022Q3 us-gaap Assets Current
AssetsCurrent
67347840
CY2021Q4 us-gaap Assets Current
AssetsCurrent
100204637
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1798212
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2392696
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4074074
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4609110
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
133055
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46385
CY2022Q3 us-gaap Assets
Assets
73830606
CY2021Q4 us-gaap Assets
Assets
107730253
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
767938
CY2021Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3093344
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17469209
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17007529
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9385847
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1374220
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1782277
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4833839
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10093312
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
133710
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
133710
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1243802
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1136948
CY2022Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
9883638
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15636275
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5007236
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5956217
CY2022Q3 us-gaap Liabilities
Liabilities
31884497
CY2021Q4 us-gaap Liabilities
Liabilities
38622226
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125280881
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125280881
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125230881
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125230881
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
12528
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12523
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
423342069
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
418891713
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-381201614
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349733764
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-206874
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-62445
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
41946109
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73830606
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107730253
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97323
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
881705
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4108190
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8695641
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9894068
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30681684
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4073266
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
5000000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5277090
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14144557
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16190684
CY2022Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2021Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-29038625
us-gaap Operating Income Loss
OperatingIncomeLoss
-45990663
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
77712
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8181456
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
13972731
us-gaap Operating Expenses
OperatingExpenses
29038625
us-gaap Operating Expenses
OperatingExpenses
46872368
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8181456
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13875408
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12033031
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-324322
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11790328
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-541889
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-391867
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1491137
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1439587
CY2022Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
CY2021Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
472143
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
670143
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-136087
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-414048
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-613766
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-409914
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-600264
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11699259
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2429225
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10610970
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-8781720
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-2176149
us-gaap Profit Loss
ProfitLoss
-31467850
us-gaap Profit Loss
ProfitLoss
-35379693
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125268381
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125268381
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125209985
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125209985
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125255927
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125255927
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122234847
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35388660
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122234847
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8781720
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2176149
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
49469857
CY2022Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Net Income Loss
NetIncomeLoss
-31467850
us-gaap Net Income Loss
NetIncomeLoss
-35379693
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-87554
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-3513
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1345526
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-87554
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-87554
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3513
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-144429
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8967
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
670143
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-144429
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8967
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8869274
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2179662
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31612279
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8781720
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
41946109
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
76959201
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2599247
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
250000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3513
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2176149
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
77628786
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4450361
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-144429
us-gaap Net Income Loss
NetIncomeLoss
-31467850
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
41946109
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45274925
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1820437
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59110801
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7686921
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
944799
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8967
us-gaap Net Income Loss
NetIncomeLoss
-35379693
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
77628786
us-gaap Net Income Loss
NetIncomeLoss
-31467850
us-gaap Net Income Loss
NetIncomeLoss
-35379693
us-gaap Share Based Compensation
ShareBasedCompensation
4450361
us-gaap Share Based Compensation
ShareBasedCompensation
7686921
us-gaap Depreciation And Amortization
DepreciationAndAmortization
578598
us-gaap Depreciation And Amortization
DepreciationAndAmortization
792132
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
232844
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
606078
crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
-829235
crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
-493722
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
535037
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
361327
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
539867
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
471954
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-177939
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
521497
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-21235
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9099
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1438849
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1601003
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
881704
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
86670
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-234037
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1237294
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5196591
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5259474
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8387299
crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-842127
crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-743462
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30089450
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38481122
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
88738150
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
77266596
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
107037899
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
7019756
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13449
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8100
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7700
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18294400
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70239140
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
767937
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
710158
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62586070
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1820437
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-767937
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60055475
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12562987
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48664787
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25676532
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86453341
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13113545
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37788554
us-gaap Interest Paid Net
InterestPaidNet
1407208
us-gaap Interest Paid Net
InterestPaidNet
1305512
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NATURE OF OPERATIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is focused on the development of immune modulators that will have application in disease states spanning from immuno-oncology to fibrosis. Corbus’ current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. The Company plans to expand its pipeline in immuno-oncology through internal efforts and business development. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. In the opinion of management of the Company, the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments (which include only normal recurring adjustments) necessary to present fairly, in all material respects, the consolidated financial position of the Company as of September 30, 2022 and the results of its operations and changes in stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements. The Company prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (the “SEC”) for interim reporting. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP) have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 8, 2022 (the “2021 Annual Report”). The results of operations for such interim periods are not necessarily indicative of the operating results for the full fiscal year.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is continuing to monitor the impact of the COVID-19 pandemic on its business and operations.</span></p>
CY2022Q3 crbp Cash And Cash Equivalents And Marketable Debt Securities
CashAndCashEquivalentsAndMarketableDebtSecurities
66229000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock-based compensation, the accrual of research, product development and clinical obligations, lease obligations, and the valuation of warrants discussed in Note 14.</span></p>
CY2022Q3 us-gaap Cash
Cash
3806107
CY2021Q4 us-gaap Cash
Cash
6751593
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8637538
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18255039
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12443645
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25006632
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
669900
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
669900
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13113545
us-gaap Net Income Loss
NetIncomeLoss
-35379693
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125268381
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25676532
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125209985
CY2021Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
606000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
380000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However, the Company believes the risk of loss is minimal as these banks are large financial institutions.</span></p>
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
226000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8781720
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2176149
us-gaap Net Income Loss
NetIncomeLoss
-31467850
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125255927
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122234847
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q3 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
53993000
CY2022Q3 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-0
CY2022Q3 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
207000
CY2022Q3 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
53786000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
53993000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
53786000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
53993000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
53786000
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
72703
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
62
CY2021Q4 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
72641
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
44859000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
44848000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
11092000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
11041000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55951000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55889000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4707038
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
252333
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1033557
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4764938
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2908826
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2372242
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1798212
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2392696
CY2022Q3 us-gaap Depreciation
Depreciation
190795
CY2021Q3 us-gaap Depreciation
Depreciation
256286
us-gaap Depreciation
Depreciation
578598
us-gaap Depreciation
Depreciation
792132
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
415118
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1700005
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1747447
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1794889
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1688144
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7345603
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1094565
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6251038
crbp Sublease Agreement Description
SubleaseAgreementDescription
Effective August 26, 2021, the Company entered into a sublease agreement with a third party to sublease 12,112 square feet of the 30,023 square feet currently being leased under one of its two existing lease agreements. The sublease commenced on October 1, 2021 and ends October 31, 2026. The Company notes sublease income of $55,133 and $165,398 for the three and nine months ended September 30, 2022, respectively was recognized and offset against rent expense.
CY2021Q3 crbp Sublease Area
SubleaseArea
12112
CY2021Q3 crbp Sublease Area Total
SubleaseAreaTotal
30023
CY2022Q3 crbp Subleases Income
SubleasesIncome
55133
crbp Subleases Income
SubleasesIncome
165398
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
26243
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
185717
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
278576
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
290688
CY2022Q2 crbp Settlement Of Disputes With Venn Therapeutics Llc
SettlementOfDisputesWithVennTherapeuticsLlc
5000000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
811000
us-gaap Interest Expense Debt
InterestExpenseDebt
2193000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
686000
us-gaap Interest Expense Debt
InterestExpenseDebt
2016000
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2262388
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2262388
CY2022Q3 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
1531873
CY2021Q4 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
992007
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
19269485
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18729619
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
9883638
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3093344
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9385847
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15636275
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3021127
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9774399
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8394474
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
21190000
CY2022Q3 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
1405142
CY2021Q4 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
5435464
CY2022Q3 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
34262
CY2021Q4 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
203676
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1707393
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2715368
CY2022Q3 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
721500
CY2021Q4 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
1213699
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
965542
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
525105
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4833839
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10093312
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125280881
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125280881
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125230881
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125230881
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1345526
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2599247
us-gaap Share Based Compensation
ShareBasedCompensation
4450361
us-gaap Share Based Compensation
ShareBasedCompensation
7686921
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1345526
CY2022Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
133710
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
133710
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2599247
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4450361
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7686921
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15326105
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5298503
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1404071
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
305432
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.34
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18915105
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M20D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10981693
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
10619178
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y3M29D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3055619
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
17740623
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9640583
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.02
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
CY2022Q4 crbp Conversion Price Of Loan
ConversionPriceOfLoan
1125000

Files In Submission

Name View Source Status
0000950170-22-023282-index-headers.html Edgar Link pending
0000950170-22-023282-index.html Edgar Link pending
0000950170-22-023282.txt Edgar Link pending
0000950170-22-023282-xbrl.zip Edgar Link pending
crbp-20220930.htm Edgar Link pending
crbp-20220930.xsd Edgar Link pending
crbp-ex31_1.htm Edgar Link pending
crbp-ex31_2.htm Edgar Link pending
crbp-ex32_1.htm Edgar Link pending
crbp-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
crbp-20220930_cal.xml Edgar Link unprocessable
crbp-20220930_def.xml Edgar Link unprocessable
crbp-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crbp-20220930_lab.xml Edgar Link unprocessable
crbp-20220930_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending